| Package | hl7.fhir.us.breastcancer |
| Type | StructureDefinition |
| Id | oncology-ProgesteroneReceptorNuclearPositivity-model |
| FHIR Version | R3 |
| Source | http://hl7.org/fhir/us/breastcancer/http://hl7.org/fhir/us/breastcancer/2018Sep/StructureDefinition-oncology-ProgesteroneReceptorNuclearPositivity-model.html |
| URL | http://hl7.org/fhir/us/breastcancer/StructureDefinition/oncology-ProgesteroneReceptorNuclearPositivity-model |
| Version | 0.2.0 |
| Status | draft |
| Date | 2018-08-17T00:00:00+10:00 |
| Name | ProgesteroneReceptorNuclearPositivityModel |
| Title | BC ProgesteroneReceptorNuclearPositivity Logical Model |
| Realm | us |
| Authority | hl7 |
| Description | The percentage of cells that test (stain) positive for the presence of progesterone receptors. We are seeking feedback on whether nuclear positivity should be an exact percentage or a range of percentages. As currently defined, an exact nuclear positivity could be represented by a zero-width range, where the lower and upper bounds would be the same number. We are seeking feedback on whether nuclear positivity should be an exact percentage or a range of percentages. As currently defined, an exact nuclear positivity could be represented by a zero-width range, where the lower and upper bounds would be the same number. |
| Type | oncology-ProgesteroneReceptorNuclearPositivity-model |
| Kind | logical |
| StructureDefinition | |
| oncology-ProgesteroneReceptorStatus-model | BC ProgesteroneReceptorStatus Logical Model |
| StructureDefinition | |
| cimi-topic-ReferenceRange-model | BC ReferenceRange Logical Model |
| shr-core-Range-model | BC Range Logical Model |
Note: links and images are rebased to the (stated) source
BC ProgesteroneReceptorNuclearPositivity Logical Model
The percentage of cells that test (stain) positive for the presence of progesterone receptors. We are seeking feedback on whether nuclear positivity should be an exact percentage or a range of percentages. As currently defined, an exact nuclear positivity could be represented by a zero-width range, where the lower and upper bounds would be the same number. We are seeking feedback on whether nuclear positivity should be an exact percentage or a range of percentages. As currently defined, an exact nuclear positivity could be represented by a zero-width range, where the lower and upper bounds would be the same number.
FHIR{
"resourceType": "StructureDefinition",
"id": "oncology-ProgesteroneReceptorNuclearPositivity-model",
"text": {
"status": "generated",
"div": "<!-- snip (see above) -->"
},
"url": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/oncology-ProgesteroneReceptorNuclearPositivity-model",
"identifier": [
{
"system": "http://hl7.org/fhir/us/breastcancer",
"value": "oncology.ProgesteroneReceptorNuclearPositivity"
}
],
"version": "0.2.0",
"name": "ProgesteroneReceptorNuclearPositivityModel",
"title": "BC ProgesteroneReceptorNuclearPositivity Logical Model",
"status": "draft",
"date": "2018-08-17T00:00:00+10:00",
"publisher": "The HL7 Cancer Interoperability Group sponsored by Clinical Interoperability Council Work Group (CIC)",
"contact": [
{
"telecom": [
{
"system": "url",
"value": "http://www.hl7.org/Special/committees/cic/index.cfm"
}
]
}
],
"description": "The percentage of cells that test (stain) positive for the presence of progesterone receptors. We are seeking feedback on whether nuclear positivity should be an exact percentage or a range of percentages. As currently defined, an exact nuclear positivity could be represented by a zero-width range, where the lower and upper bounds would be the same number. We are seeking feedback on whether nuclear positivity should be an exact percentage or a range of percentages. As currently defined, an exact nuclear positivity could be represented by a zero-width range, where the lower and upper bounds would be the same number.",
"keyword": [
{
"system": "http://loinc.org",
"code": "14230-7",
"display": "Cells.progesterone receptor/100 cells in Tissue by Immune stain"
}
],
"kind": "logical",
"abstract": false,
"type": "oncology-ProgesteroneReceptorNuclearPositivity-model",
"baseDefinition": "http://hl7.org/fhir/StructureDefinition/Element",
"derivation": "specialization",
"snapshot": {
"element": [
{
"id": "oncology-ProgesteroneReceptorNuclearPositivity-model",
"path": "oncology-ProgesteroneReceptorNuclearPositivity-model",
"definition": "The percentage of cells that test (stain) positive for the presence of progesterone receptors. We are seeking feedback on whether nuclear positivity should be an exact percentage or a range of percentages. As currently defined, an exact nuclear positivity could be represented by a zero-width range, where the lower and upper bounds would be the same number. We are seeking feedback on whether nuclear positivity should be an exact percentage or a range of percentages. As currently defined, an exact nuclear positivity could be represented by a zero-width range, where the lower and upper bounds would be the same number.",
"min": 0,
"max": "*",
"base": {
"path": "oncology-ProgesteroneReceptorNuclearPositivity-model",
"min": 0,
"max": "*"
},
"mustSupport": false,
"isModifier": false,
"isSummary": false
},
{
"id": "oncology-ProgesteroneReceptorNuclearPositivity-model.value",
"path": "oncology-ProgesteroneReceptorNuclearPositivity-model.value",
"short": "Range representing the percentage of cells that test (stain) positive for the presence of progesterone receptors. We are seeking feedback on whether nuclear positivity should be an exact percentage or a range of percentages. As currently defined, an exact nuclear positivity could be represented by a zero-width range, where the lower and upper bounds would be the same number. We are seeking feedback on whether nuclear positivity should be an exact percentage or a range of percentages. As currently defined, an exact nuclear positivity could be represented by a zero-width range, where the lower and upper bounds would be the same number.",
"definition": "Range representing the percentage of cells that test (stain) positive for the presence of progesterone receptors. We are seeking feedback on whether nuclear positivity should be an exact percentage or a range of percentages. As currently defined, an exact nuclear positivity could be represented by a zero-width range, where the lower and upper bounds would be the same number. We are seeking feedback on whether nuclear positivity should be an exact percentage or a range of percentages. As currently defined, an exact nuclear positivity could be represented by a zero-width range, where the lower and upper bounds would be the same number.",
"min": 1,
"max": "1",
"base": {
"path": "oncology-ProgesteroneReceptorNuclearPositivity-model.value",
"min": 1,
"max": "1"
},
"type": [
{
"code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/shr-core-Range-model"
}
],
"mustSupport": false,
"isModifier": false,
"isSummary": false
},
{
"id": "oncology-ProgesteroneReceptorNuclearPositivity-model.topicCode",
"path": "oncology-ProgesteroneReceptorNuclearPositivity-model.topicCode",
"short": "The concept representing the finding or action that is the topic of the statement.",
"definition": "The concept representing the finding or action that is the topic of the statement.\n\nFor action topics, the TopicCode represents the action being described. For findings, the TopicCode represents the 'question' or property being investigated. For evaluation result findings, the TopicCode contains a concept for an observable entity, such as systolic blood pressure. For assertion findings, the TopicCode contains a code representing the condition, allergy, or other item being asserted. In all cases, the TopicCode describes the topic independent of the context of the action or the finding.",
"min": 0,
"max": "1",
"base": {
"path": "oncology-ProgesteroneReceptorNuclearPositivity-model.topicCode",
"min": 0,
"max": "1"
},
"type": [
{
"code": "Coding"
}
],
"mustSupport": false,
"isModifier": false,
"isSummary": false
},
{
"id": "oncology-ProgesteroneReceptorNuclearPositivity-model.exceptionValue",
"path": "oncology-ProgesteroneReceptorNuclearPositivity-model.exceptionValue",
"short": "Reason that a value associated with a test or other finding is missing.",
"definition": "Reason that a value associated with a test or other finding is missing.",
"min": 0,
"max": "1",
"base": {
"path": "oncology-ProgesteroneReceptorNuclearPositivity-model.exceptionValue",
"min": 0,
"max": "1"
},
"type": [
{
"code": "Coding"
}
],
"mustSupport": false,
"isModifier": false,
"isSummary": false,
"binding": {
"strength": "extensible",
"valueSetReference": {
"reference": "http://hl7.org/fhir/ValueSet/data-absent-reason"
}
}
},
{
"id": "oncology-ProgesteroneReceptorNuclearPositivity-model.interpretation",
"path": "oncology-ProgesteroneReceptorNuclearPositivity-model.interpretation",
"code": [
{
"system": "http://ncimeta.nci.nih.gov",
"code": "C0420833"
}
],
"short": "A clinical interpretation of a finding (applies to both assertions and observation).",
"definition": "A clinical interpretation of a finding (applies to both assertions and observation).",
"min": 0,
"max": "1",
"base": {
"path": "oncology-ProgesteroneReceptorNuclearPositivity-model.interpretation",
"min": 0,
"max": "1"
},
"type": [
{
"code": "Coding"
}
],
"mustSupport": false,
"isModifier": false,
"isSummary": false,
"binding": {
"strength": "extensible",
"valueSetReference": {
"reference": "http://hl7.org/fhir/ValueSet/observation-interpretation"
}
}
},
{
"id": "oncology-ProgesteroneReceptorNuclearPositivity-model.referenceRange",
"path": "oncology-ProgesteroneReceptorNuclearPositivity-model.referenceRange",
"code": [
{
"system": "http://ncimeta.nci.nih.gov",
"code": "C0883335"
}
],
"short": "The usual or acceptable range for a test result.",
"definition": "The usual or acceptable range for a test result.",
"min": 0,
"max": "0",
"base": {
"path": "oncology-ProgesteroneReceptorNuclearPositivity-model.referenceRange",
"min": 0,
"max": "0"
},
"type": [
{
"code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/cimi-topic-ReferenceRange-model"
}
],
"mustSupport": false,
"isModifier": false,
"isSummary": false
}
]
},
"differential": {
"element": [
{
"id": "oncology-ProgesteroneReceptorNuclearPositivity-model",
"path": "oncology-ProgesteroneReceptorNuclearPositivity-model",
"definition": "The percentage of cells that test (stain) positive for the presence of progesterone receptors. We are seeking feedback on whether nuclear positivity should be an exact percentage or a range of percentages. As currently defined, an exact nuclear positivity could be represented by a zero-width range, where the lower and upper bounds would be the same number. We are seeking feedback on whether nuclear positivity should be an exact percentage or a range of percentages. As currently defined, an exact nuclear positivity could be represented by a zero-width range, where the lower and upper bounds would be the same number.",
"min": 0,
"max": "*",
"base": {
"path": "oncology-ProgesteroneReceptorNuclearPositivity-model",
"min": 0,
"max": "*"
},
"mustSupport": false,
"isModifier": false,
"isSummary": false
},
{
"id": "oncology-ProgesteroneReceptorNuclearPositivity-model.value",
"path": "oncology-ProgesteroneReceptorNuclearPositivity-model.value",
"short": "Range representing the percentage of cells that test (stain) positive for the presence of progesterone receptors. We are seeking feedback on whether nuclear positivity should be an exact percentage or a range of percentages. As currently defined, an exact nuclear positivity could be represented by a zero-width range, where the lower and upper bounds would be the same number. We are seeking feedback on whether nuclear positivity should be an exact percentage or a range of percentages. As currently defined, an exact nuclear positivity could be represented by a zero-width range, where the lower and upper bounds would be the same number.",
"definition": "Range representing the percentage of cells that test (stain) positive for the presence of progesterone receptors. We are seeking feedback on whether nuclear positivity should be an exact percentage or a range of percentages. As currently defined, an exact nuclear positivity could be represented by a zero-width range, where the lower and upper bounds would be the same number. We are seeking feedback on whether nuclear positivity should be an exact percentage or a range of percentages. As currently defined, an exact nuclear positivity could be represented by a zero-width range, where the lower and upper bounds would be the same number.",
"min": 1,
"max": "1",
"base": {
"path": "oncology-ProgesteroneReceptorNuclearPositivity-model.value",
"min": 1,
"max": "1"
},
"type": [
{
"code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/shr-core-Range-model"
}
],
"mustSupport": false,
"isModifier": false,
"isSummary": false
},
{
"id": "oncology-ProgesteroneReceptorNuclearPositivity-model.topicCode",
"path": "oncology-ProgesteroneReceptorNuclearPositivity-model.topicCode",
"short": "The concept representing the finding or action that is the topic of the statement.",
"definition": "The concept representing the finding or action that is the topic of the statement.\n\nFor action topics, the TopicCode represents the action being described. For findings, the TopicCode represents the 'question' or property being investigated. For evaluation result findings, the TopicCode contains a concept for an observable entity, such as systolic blood pressure. For assertion findings, the TopicCode contains a code representing the condition, allergy, or other item being asserted. In all cases, the TopicCode describes the topic independent of the context of the action or the finding.",
"min": 0,
"max": "1",
"base": {
"path": "oncology-ProgesteroneReceptorNuclearPositivity-model.topicCode",
"min": 0,
"max": "1"
},
"type": [
{
"code": "Coding"
}
],
"mustSupport": false,
"isModifier": false,
"isSummary": false
},
{
"id": "oncology-ProgesteroneReceptorNuclearPositivity-model.exceptionValue",
"path": "oncology-ProgesteroneReceptorNuclearPositivity-model.exceptionValue",
"short": "Reason that a value associated with a test or other finding is missing.",
"definition": "Reason that a value associated with a test or other finding is missing.",
"min": 0,
"max": "1",
"base": {
"path": "oncology-ProgesteroneReceptorNuclearPositivity-model.exceptionValue",
"min": 0,
"max": "1"
},
"type": [
{
"code": "Coding"
}
],
"mustSupport": false,
"isModifier": false,
"isSummary": false,
"binding": {
"strength": "extensible",
"valueSetReference": {
"reference": "http://hl7.org/fhir/ValueSet/data-absent-reason"
}
}
},
{
"id": "oncology-ProgesteroneReceptorNuclearPositivity-model.interpretation",
"path": "oncology-ProgesteroneReceptorNuclearPositivity-model.interpretation",
"code": [
{
"system": "http://ncimeta.nci.nih.gov",
"code": "C0420833"
}
],
"short": "A clinical interpretation of a finding (applies to both assertions and observation).",
"definition": "A clinical interpretation of a finding (applies to both assertions and observation).",
"min": 0,
"max": "1",
"base": {
"path": "oncology-ProgesteroneReceptorNuclearPositivity-model.interpretation",
"min": 0,
"max": "1"
},
"type": [
{
"code": "Coding"
}
],
"mustSupport": false,
"isModifier": false,
"isSummary": false,
"binding": {
"strength": "extensible",
"valueSetReference": {
"reference": "http://hl7.org/fhir/ValueSet/observation-interpretation"
}
}
},
{
"id": "oncology-ProgesteroneReceptorNuclearPositivity-model.referenceRange",
"path": "oncology-ProgesteroneReceptorNuclearPositivity-model.referenceRange",
"code": [
{
"system": "http://ncimeta.nci.nih.gov",
"code": "C0883335"
}
],
"short": "The usual or acceptable range for a test result.",
"definition": "The usual or acceptable range for a test result.",
"min": 0,
"max": "0",
"base": {
"path": "oncology-ProgesteroneReceptorNuclearPositivity-model.referenceRange",
"min": 0,
"max": "0"
},
"type": [
{
"code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/cimi-topic-ReferenceRange-model"
}
],
"mustSupport": false,
"isModifier": false,
"isSummary": false
}
]
}
}